Preelumina’s vision is to improve women’s health by developing tools for the effective prediction and diagnosis of the disease as well as a cure for preeclampsia. Preelumina has identified a novel biological marker, free fetal hemoglobin, of preeclampsia and based on this developed a diagnostic test. Results so far show that this marker can be used as a diagnostic marker of preeclampsia while also enabling early prognosis during pregnancy. Preelumina has investigated the mechanisms behind the development of preeclampsia and identified a unique treatment method based on an endogenous protein which is under development. This could be the very first treatment of preeclampsia that is directed against the primary causes of the disease and not only its symptoms.

In 2007 Preelumina received the Lund University Innovation Prize and Innovationsbron Syds Idéstipendium.